Skip to main content
. 2021 Mar 11;26(8):635–639. doi: 10.1002/onco.13715

Figure 2.

Figure 2

The schematic reveals that although HER2 mutations induce biochemical resistance to conventional anti‐HER2 drugs such as trastuzumab and lapatinib by activating downstream cell signaling pathways, they may also enhance internalization of the HER2 protein and the consequent endocytosis of the HER2–ADC complex and release of the ADC payload in both HER2‐mutant and HER2‐amplified tumors.